Darvocet ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
70. Spinal stenosis
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00652093 (ClinicalTrials.gov) | March 2008 | 11/3/2008 | Lumbar Stenosis Outcomes Research II | Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial | Lumbar Spinal Stenosis | Drug: opana then darvocet then placebo;Drug: opana then placebo then darvocet;Drug: placebo then opana then darvocet;Drug: Placebo then darvocet then opana;Drug: Darvocet then opana then placebo;Drug: Darvocet then placebo then opana | University of Rochester | Endo Pharmaceuticals | Terminated | 50 Years | N/A | All | 24 | Phase 4 | United States |